Update on Recommendations for Assessing Response from the Third International Workshop on Waldenström's Macroglobulinemia-Reference-Cited by-同舟云学术

Update on Recommendations for Assessing Response from the Third International Workshop on Waldenström's Macroglobulinemia

Published:2006-03 Issue:5 Volume:6 Page:380-383
ISSN:1557-9190
Container-title:Clinical Lymphoma and Myeloma
language:en
Short-container-title:Clinical Lymphoma and Myeloma

Author:

Kimby Eva,Treon Steven P.,Anagnostopoulos Athanasios,Dimopoulos Meletios,Garcia-Sanz Ramon,Gertz Morie A.,Johnson Stephen,LeBlond Veronique,Fermand Jean-Paul,Maloney David G.,Merlini Giampaolo,Morel Pierre,Morra Enrica,Nichols Gwen,Ocio Enrique M.,Owen Roger,Stone Marvin,Bladé Joan

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference17 articles.

1. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia;Kyle;Semin Oncol,2003

2. Uniform Response Criteria in Waldenstrom's Macroglobulinemia. Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia;Weber;Semin Oncol,2003

3. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia;Gertz;Semin Oncol,2003

4. Waldenstrom's macroglobulinemia;Merlini,2004

5. Diagnosis and management of Waldenstrom's macroglobulinemia;Dimopoulos;J Clin Oncol,2005

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Management of Relapsed or Refractory Waldenström’s Macroglobulinemia;Hematology/Oncology Clinics of North America;2023-08

2. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia;Journal of Clinical Oncology;2023-05-10

3. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study;Journal of Clinical Oncology;2022-01-01

4. Safety and antitumor activity of acalabrutinib for relapsed/refractory B‐cell malignancies: A Japanese phase I study;Cancer Science;2021-05-07

5. Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis;Clinical Lymphoma Myeloma and Leukemia;2020-10